NanoViricides, Inc. (NNVC)
USD 1.5
(0.67%)
USD 1.5
(0.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -7.75 Million USD | 1.06% |
| 2023 | -7.84 Million USD | -6.26% |
| 2022 | -7.37 Million USD | 8.12% |
| 2021 | -8.03 Million USD | -8.19% |
| 2020 | -7.29 Million USD | 6.14% |
| 2019 | -7.96 Million USD | 7.45% |
| 2018 | -8.59 Million USD | 3.74% |
| 2017 | -8.93 Million USD | -9.09% |
| 2016 | -8.19 Million USD | -23.3% |
| 2015 | -6.76 Million USD | 20.34% |
| 2014 | -8.45 Million USD | -31.18% |
| 2013 | -7.56 Million USD | -10.99% |
| 2012 | -5.98 Million USD | 2.57% |
| 2011 | -5.94 Million USD | -15.81% |
| 2010 | -4.64 Million USD | -79.61% |
| 2009 | -2.83 Million USD | -1.04% |
| 2008 | -2.73 Million USD | 8.8% |
| 2007 | -3.02 Million USD | -19.41% |
| 2006 | -2.55 Million USD | -3765.3% |
| 2005 | -66 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.74 Million USD | 48.45% |
| 2024 Q4 | -2.16 Million USD | -30.09% |
| 2024 Q3 | -1.71 Million USD | 12.96% |
| 2024 Q2 | -1.99 Million USD | -9.7% |
| 2023 Q3 | -1.51 Million USD | 2.8% |
| 2023 Q4 | -3.38 Million USD | -123.25% |
| 2023 Q2 | -1.55 Million USD | -12.39% |
| 2023 Q1 | -1.38 Million USD | 12.97% |
| 2023 FY | - USD | -6.26% |
| 2022 Q1 | -2.43 Million USD | -28.53% |
| 2022 FY | - USD | 8.12% |
| 2022 Q4 | -1.59 Million USD | 0.83% |
| 2022 Q2 | -1.74 Million USD | 28.52% |
| 2022 Q3 | -1.6 Million USD | 7.74% |
| 2021 Q2 | -2.11 Million USD | -1.23% |
| 2021 Q3 | -1.92 Million USD | 8.81% |
| 2021 Q1 | -2.09 Million USD | -26.29% |
| 2021 Q4 | -1.89 Million USD | 1.78% |
| 2021 FY | - USD | -8.19% |
| 2020 Q4 | -1.65 Million USD | 29.82% |
| 2020 FY | - USD | 6.14% |
| 2020 Q1 | -2.23 Million USD | -12.56% |
| 2020 Q2 | -1.6 Million USD | 28.33% |
| 2020 Q3 | -2.35 Million USD | -47.26% |
| 2019 Q2 | -2.17 Million USD | -18.23% |
| 2019 Q3 | -1.89 Million USD | 12.84% |
| 2019 FY | - USD | 7.45% |
| 2019 Q4 | -1.98 Million USD | -4.5% |
| 2019 Q1 | -1.84 Million USD | 11.49% |
| 2018 FY | - USD | 3.74% |
| 2018 Q4 | -2.08 Million USD | 6.34% |
| 2018 Q3 | -2.22 Million USD | -1.09% |
| 2018 Q2 | -2.2 Million USD | -7.96% |
| 2018 Q1 | -2.03 Million USD | 1.19% |
| 2017 Q4 | -2.06 Million USD | 15.2% |
| 2017 FY | - USD | -9.09% |
| 2017 Q1 | -2.26 Million USD | 2.22% |
| 2017 Q2 | -2.12 Million USD | 6.17% |
| 2017 Q3 | -2.43 Million USD | -14.65% |
| 2016 Q3 | -1.84 Million USD | 4.2% |
| 2016 Q2 | -1.92 Million USD | 6.25% |
| 2016 FY | - USD | -23.3% |
| 2016 Q4 | -2.31 Million USD | -25.43% |
| 2016 Q1 | -2.05 Million USD | 10.35% |
| 2015 Q4 | -2.28 Million USD | -121.38% |
| 2015 Q2 | -1.68 Million USD | -5.47% |
| 2015 FY | - USD | 20.34% |
| 2015 Q3 | -1.03 Million USD | 38.49% |
| 2015 Q1 | -1.59 Million USD | 56.3% |
| 2014 Q3 | -1.13 Million USD | 32.76% |
| 2014 FY | - USD | -31.18% |
| 2014 Q4 | -3.64 Million USD | -222.69% |
| 2014 Q2 | -1.68 Million USD | 7.84% |
| 2014 Q1 | -1.82 Million USD | -25.63% |
| 2013 Q2 | -1.2 Million USD | 8.67% |
| 2013 Q4 | -1.45 Million USD | 32.01% |
| 2013 Q3 | -2.13 Million USD | -76.73% |
| 2013 FY | - USD | -10.99% |
| 2013 Q1 | -1.32 Million USD | 4.75% |
| 2012 Q1 | -1.07 Million USD | -20.79% |
| 2012 FY | - USD | 2.57% |
| 2012 Q4 | -1.38 Million USD | 31.78% |
| 2012 Q3 | -2.03 Million USD | -68.61% |
| 2012 Q2 | -1.2 Million USD | -12.11% |
| 2011 Q3 | -2.5 Million USD | -64.64% |
| 2011 Q1 | -1.05 Million USD | -30.78% |
| 2011 FY | - USD | -15.81% |
| 2011 Q2 | -1.52 Million USD | -43.77% |
| 2011 Q4 | -891.67 Thousand USD | 64.4% |
| 2010 Q1 | -728.19 Thousand USD | -17.05% |
| 2010 Q4 | -809.16 Thousand USD | 66.14% |
| 2010 Q3 | -2.38 Million USD | -158.98% |
| 2010 Q2 | -922.7 Thousand USD | -26.71% |
| 2010 FY | - USD | -79.61% |
| 2009 Q2 | -641.51 Thousand USD | 15.05% |
| 2009 Q4 | -622.14 Thousand USD | 21.1% |
| 2009 Q1 | -755.2 Thousand USD | 23.73% |
| 2009 FY | - USD | -1.04% |
| 2009 Q3 | -788.56 Thousand USD | -22.92% |
| 2008 Q3 | -803.26 Thousand USD | -98.96% |
| 2008 Q2 | -403.73 Thousand USD | 30.55% |
| 2008 FY | - USD | 8.8% |
| 2008 Q4 | -990.19 Thousand USD | -23.27% |
| 2008 Q1 | -581.36 Thousand USD | 22.17% |
| 2007 FY | - USD | -19.41% |
| 2007 Q2 | -705.82 Thousand USD | -5.96% |
| 2007 Q3 | -927.68 Thousand USD | -31.43% |
| 2007 Q4 | -746.94 Thousand USD | 19.48% |
| 2007 Q1 | -666.15 Thousand USD | 40.52% |
| 2006 Q4 | -1.11 Million USD | -42.05% |
| 2006 FY | - USD | -3765.3% |
| 2006 Q3 | -788.37 Thousand USD | 14.23% |
| 2006 Q2 | -919.12 Thousand USD | -101.11% |
| 2006 Q1 | -457.03 Thousand USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 75.513% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 80.567% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 84.829% |
| Azitra, Inc. | -10.67 Million USD | 27.322% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | 5.17% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -13.04% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 72.877% |
| CEL-SCI Corporation | -27.56 Million USD | 71.854% |
| iBio, Inc. | -14.02 Million USD | 44.675% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 68.637% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 61.565% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 66.015% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 44.093% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -61.606% |
| Oragenics, Inc. | -20.87 Million USD | 62.845% |
| BiomX Inc. | -22.81 Million USD | 66.0% |
| BiomX Inc. | -22.81 Million USD | 66.0% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 166.579% |
| Palatin Technologies, Inc. | -29.03 Million USD | 73.28% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 77.889% |